BioCentury
ARTICLE | Clinical News

IB-MECA: Additional Phase II/III data

May 11, 2015 7:00 AM UTC

Additional data from a double-blind, international Phase II/III trial in 326 patients with moderate to severe plaque psoriasis showed that twice-daily oral CF101 led to a 57% mean improvement in PASI ...